| 1.53 0.08 (5.52%) | 06-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.98 |
1-year : | 2.31 |
| Resists | First : | 1.7 |
Second : | 1.98 |
| Pivot price | 1.45 |
|||
| Supports | First : | 1.48 |
Second : | 1.35 |
| MAs | MA(5) : | 1.48 |
MA(20) : | 1.47 |
| MA(100) : | 2.34 |
MA(250) : | 4.34 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 51.7 |
D(3) : | 47.1 |
| RSI | RSI(14): 49 |
|||
| 52-week | High : | 12.23 | Low : | 1.28 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SXTP ] has closed below upper band by 4.7%. Bollinger Bands are 89.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 43 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.59 - 1.6 | 1.6 - 1.61 |
| Low: | 1.43 - 1.44 | 1.44 - 1.45 |
| Close: | 1.51 - 1.53 | 1.53 - 1.55 |
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
Wed, 03 Jun 2026
60 Degrees Pharmaceuticals to seek Priority Review Voucher if tafenoquine trial supports NDA - TradingView
Wed, 03 Jun 2026
60 Degrees Pharmaceuticals (SXTP) details potential NDA and FDA voucher path - Stock Titan
Tue, 26 May 2026
60 Degrees Pharmaceuticals enrolls first patient in babesiosis trial - Investing.com
Tue, 26 May 2026
First patient joins 2026 babesiosis trial as tick bites hit highs - Stock Titan
Tue, 26 May 2026
60 Degrees Pharmaceuticals Announces Early Enrollment of - GlobeNewswire
Mon, 18 May 2026
Eric Francois joins 60 Degrees Pharmaceuticals (SXTP) board with deep biotech finance background - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 2.44e+006 (%) |
| Held by Institutions | 0.8 (%) |
| Shares Short | 182 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.85e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 292.4 % |
| Return on Equity (ttm) | -78 % |
| Qtrly Rev. Growth | 1.31e+006 % |
| Gross Profit (p.s.) | -13.63 |
| Sales Per Share | -64.01 |
| EBITDA (p.s.) | -555556 |
| Qtrly Earnings Growth | -6.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | -2.3 |
| Dividend | 0 |
| Forward Dividend | 141530 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|